Why Teleflex (TFX) Is Down 10.6% After $403.9 Million Goodwill Impairment and Lowered Outlook

• Teleflex Incorporated reported third-quarter 2025 results that included a substantial non-cash goodwill impairment charge of US$403.9 million, a narrowed full-year earnings and revenue outlook, and sales of US$913.02 million for the quarter.
• Despite posting higher quarterly sales year-over-year, the company experienced a significant swing from net income to net loss, highlighting the financial impact of impairment charges and lower-than-expected demand in key product lines.
• We'll explore how the large goodwill impairment and revised outlook reshape Teleflex's investment narrative and future growth assumptions.

Trump has pledged to "unleash" American oil and gas and these 22 US stocks have developments that are poised to benefit.

Teleflex Investment Narrative Recap

To be a shareholder in Teleflex today, you need to believe in its long-term potential for recovery and innovation despite current challenges. The recent goodwill impairment and revised outlook do impact the narrative but don’t fundamentally alter the biggest short-term catalysts, such as the integration of BIOTRONIK Vascular, while intensifying focus on ongoing demand weakness as the key risk to watch.

Of the latest announcements, the narrowing of full-year revenue and earnings guidance stands out as most relevant, reflecting pressure from lower-than-expected intra-aortic balloon pump demand and significant impairment charges. This shift aligns closely with concerns about persistent softness in core product lines and its significance for near-term earnings momentum.

In contrast, one issue investors need to keep in mind is the risk that ongoing demand weakness in major product lines...

Read the full narrative on Teleflex (it's free!)

Teleflex's narrative projects $3.9 billion revenue and $553.0 million earnings by 2028. This requires 8.9% yearly revenue growth and a $361.1 million earnings increase from $191.9 million today.

Uncover how Teleflex's forecasts yield a $127.71 fair value, a 15% upside to its current price.

Exploring Other Perspectives

Five Simply Wall St Community fair value estimates for Teleflex cover a wide US$120 to US$458.67 range. Against this backdrop, the recent downward revision in company outlook could shape how you interpret these differing opinions on future growth and profitability.

Explore 5 other fair value estimates on Teleflex - why the stock might be worth over 4x more than the current price!

Build Your Own Teleflex Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Teleflex research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Teleflex research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Teleflex's overall financial health at a glance.

Searching For A Fresh Perspective?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

• These 13 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.
• This technology could replace computers: discover 27 stocks that are working to make quantum computing a reality.
• AI is about to change healthcare. These 32 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com